Evidence map›Paper›PMID 39850240›Full record

ArticleMaterials today. Bio2025

A screening setup to streamline

Krupansh Desai, Shrikrishnan Sankaran, Aránzazu Del Campo, Sara Trujillo

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Krupansh DesaiINM - Leibniz Institute for New Materials, Campus D2 2, Saarbrücken, 66123, Germany.
Shrikrishnan SankaranINM - Leibniz Institute for New Materials, Campus D2 2, Saarbrücken, 66123, Germany.
Aránzazu Del CampoINM - Leibniz Institute for New Materials, Campus D2 2, Saarbrücken, 66123, Germany.
Sara TrujilloINM - Leibniz Institute for New Materials, Campus D2 2, Saarbrücken, 66123, Germany.

Funding

The University of Rochester's Clinical and Translational Science InstituteUL1TR002001 · NCATS · UNIVERSITY OF ROCHESTER · PI WILSON, KAREN M., ZAND, MARTIN S · 2016 to 2024
$34.6M
NCATS NIH HHS UL1 TR002001
6 · The paper itself

Abstract

Engineered living materials (ELMs), which usually comprise bacteria, fungi, or animal cells entrapped in polymeric matrices, offer limitless possibilities in fields like drug delivery or biosensing. Determining the conditions that sustain ELM performance while ensuring compatibility with ELM hosts is essential before testing them in vivo. This is critical to reduce animal experimentation and can be achieved through

Indexed as

BiocompatibilityEngineered living materialsIn vitro cultureLiving therapeutics

Identifiers

PMID39850240
PMCPMC11755081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.